The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
Traffic · 2022-09 · 23 (9) · 442-461
DOI: 10.1111/tra.12862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Traffic, online erschienen am 15.08.2022. Verfasst von Oliver Looker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Burnet Institute, Melbourne, Australia. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Malaria, Falciparum, Parasites. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Plasmodium falciparum parasites which cause malaria, traffic hundreds of proteins into the red blood cells (RBCs) they infect. These exported proteins remodel their RBCs enabling host immune evasion through processes such as cytoadherence that greatly assist parasite survival. As resistance to all current antimalarial compounds is rising new compounds need to be identified and those that could inhibit parasite protein secretion and export would both rapidly reduce parasite virulence and ultimately lead to parasite death. To identify compounds that inhibit protein export we used transgenic parasites expressing an exported nanoluciferase reporter to screen the Medicines for Malaria Venture Malaria Box of 400 antimalarial compounds with mostly unknown targets. The most potent inhibitor identified in this screen was MMV396797 whose application led to export inhibition of both the reporter and endogenous exported proteins. MMV396797 mediated blockage of protein export and slowed the rigidification and cytoadherence of infected RBCs—modifications which are both mediated by parasite‐derived exported proteins. Overall, we have identified a new protein export inhibitor in P. falciparum whose target though unknown, could be developed into a future antimalarial that rapidly inhibits parasite virulence before eliminating parasites from the host.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Burnet Institute, Melbourne, Australia.
- School of Medicine, Deakin University, Geelong, Australia.
- Department of Immunology and Microbiology, University of Melbourne, Melbourne, Australia.
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
- Department of Medical Biology, The University of Melbourne, Parkville, Australia.
- Department of Immunology and Pathology, Monash University, Melbourne, Australia.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Looker, O., Dans, M. G., Bullen, H. E., Sleebs, B. E., Crabb, B. S., & Gilson, P. R. (2022). The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites. Traffic, 23(9), 442-461. https://doi.org/10.1111/tra.12862
Vancouver
Looker O, Dans MG, Bullen HE, Sleebs BE, Crabb BS, Gilson PR. The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites. Traffic. 2022;23(9):442-461. doi:10.1111/tra.12862
BibTeX
@article{Looker2022,
author = {Looker, Oliver and Dans, Madeline G and Bullen, Hayley E and Sleebs, Brad E and Crabb, Brendan S and Gilson, Paul R},
title = {The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites},
journal = {Traffic},
year = {2022},
volume = {23},
number = {9},
pages = {442--461},
doi = {10.1111/tra.12862}
}
EUVIMED